PRPF39 Antibody

What is PRPF39 and why is it important in RNA processing research?

PRPF39 (Pre-mRNA Processing Factor 39) is a 669 amino acid protein that contains 7 HAT repeats and belongs to the PRP39 family . It functions as a previously unrecognized alternative splicing factor that recruits U1 snRNP to weak 5' splice sites, likely by binding to GC-rich RNA near these sites . In yeast, the Prp39/Prp42 heterodimer is essential for early steps of spliceosome assembly, but in metazoans (including humans), no Prp42 ortholog exists, and PRPF39 forms a homodimer instead . This structural adaptation correlates with increased splicing complexity in higher eukaryotes, making PRPF39 particularly important for understanding evolved splicing mechanisms .

What applications are PRPF39 antibodies suitable for?

PRPF39 antibodies have been validated for multiple experimental applications:

Cell/tissue samples confirmed to express detectable levels of PRPF39 include: Raji cells, K-562 cells, COLO 320 cells, 293T cells, Cal27 xenograft, and human testis tissue .

How should PRPF39 antibodies be stored and handled for optimal performance?

For maximum stability and performance of PRPF39 antibodies:

• Store at -20°C for up to 1 year from receipt date

• Avoid repeated freeze-thaw cycles

• Most PRPF39 antibodies are supplied in PBS containing 50% glycerol and small amounts (0.02-0.1%) of sodium azide

• Some formulations may include 0.5% BSA for additional stability

• Centrifuge briefly prior to opening the vial to ensure all material is at the bottom

• When diluting, use fresh, properly buffered solutions optimized for the application

What should I expect regarding the molecular weight of PRPF39 in Western blots?

The calculated molecular weight of PRPF39 is 78 kDa, but the observed molecular weight in Western blots typically ranges from 75-85 kDa . This variation can result from:

• Post-translational modifications

• Different splice variants (PRPF39 undergoes alternative splicing)

• Protein preparation methods, including heat denaturation and reducing conditions

• Buffer systems and gel percentage used for SDS-PAGE

In validated Western blots, PRPF39 antibodies detect a band at approximately 78 kDa in Raji whole cell lysate and other human cell lines . Always include appropriate positive controls such as Raji, 293T, or human 3xFlag-PRPF39 transfected 293T cells .

How can I confirm PRPF39 antibody specificity and optimize conditions for detecting endogenous PRPF39?

To confirm antibody specificity and optimize detection:

• Validation controls:

  • Compare results with multiple PRPF39 antibodies targeting different epitopes (e.g., aa 100-400 , aa 263-312 )

  • Include PRPF39 knockdown samples as negative controls (shRNA targeting has achieved 80% knockdown efficiency)

  • Use overexpression systems (e.g., 3xFlag-PRPF39 transfected 293T) as positive controls

• Western blot optimization:

  • Use 7.5-10% SDS-PAGE for optimal resolution of the 75-85 kDa region

  • Load sufficient protein (≥30 μg of whole cell lysate)

  • For subcellular localization studies, include nuclear fraction markers (e.g., RCC1, Histone H2B) alongside PRPF39 detection

• Immunohistochemistry optimization:

  • Test multiple antigen retrieval methods (citrate buffer pH 6.0 and TE buffer pH 9.0)

  • Validate nuclear staining pattern consistent with PRPF39's known localization

  • Include tissue-specific positive controls with known PRPF39 expression

How can I design experiments to study PRPF39-dependent alternative splicing events?

To investigate PRPF39's role in alternative splicing regulation:

• PRPF39 knockdown approach:

  • Use validated shRNAs targeting PRPF39 (≥80% knockdown efficiency has been achieved)

  • Include a scrambled shRNA control

  • Verify knockdown by both Western blot and qRT-PCR

  • Perform RNA-seq to identify affected alternative splicing events

• Analysis of affected splicing events:

  • Focus on cassette exon (skipped exon) events, which are most frequently affected by PRPF39 knockdown

  • Analyze alternative 5' splice site usage, which directly reflects PRPF39's function in U1 snRNP recruitment

  • Calculate PSI (Percent Spliced In) values for cassette exons to quantify splicing changes

  • Assess 5' splice site strength using established algorithms (e.g., Yeo and Burge, 2004)

• Data interpretation framework:

  • PRPF39 knockdown typically causes decreased usage of weak 5' splice sites

  • For alternative 5' splice site events, compare the splice site strength between used and unused sites

  • For skipped exon events, analyze the 5' splice site strength of the cassette exon

  • Expect PRPF39 to promote usage of GC-rich, relatively weak 5' splice sites

What approaches can I use to study PRPF39's RNA-binding properties?

To investigate PRPF39-RNA interactions:

• Electrophoretic Mobility Shift Assay (EMSA):

  • Test binding to GC-rich RNA oligonucleotides (e.g., GGCCCCCCGG)

  • Use poly(A) RNA as a negative control

  • Determine binding affinities (Kd values) with different RNA sequences

  • PRPF39 has shown binding to GC-rich RNA with a Kd of 516 ± 256 nM

• Domain-specific binding studies:

  • Prepare separate N-terminal domain (NTD) and C-terminal domain (CTD) constructs

  • Both domains can bind GC-rich RNA but not poly(A) RNA

  • The RNA may bind at the interface between the two domains

• Sequence analysis of PRPF39-dependent 5' splice sites:

  • Extract sequences flanking 5' splice sites (100nt exonic and 150nt intronic)

  • Compare sequences from PRPF39-sensitive vs. insensitive splice sites

  • Analyze for enriched 6-mer sequences

  • PRPF39-sensitive sites are characterized by GC-rich, A-poor sequence content

How can I investigate the functional significance of PRPF39 homodimerization?

To study PRPF39 homodimerization and its functional implications:

• Structure-guided mutagenesis:

  • Based on the crystal structure of murine PRPF39 (resolved at 3.3 Å)

  • Introduce point mutations at the dimerization interface

  • Validate disruption of dimerization biochemically

  • Test the effect of monomeric PRPF39 mutants on splicing in vitro

• Comparative structural analysis:

  • Compare the homodimerization mode of metazoan PRPF39 with the heterodimerization of yeast Prp39/Prp42

  • Analyze the interaction interface with U1 snRNP components, particularly U1C

  • Structure-function correlation reveals that monomeric PRPF39 mutants have detrimental effects on splicing

• Evolutionary analysis:

  • Correlate the presence of PRPF39 homodimer vs. Prp39/Prp42 heterodimer with U1 snRNA length

  • Organisms with a PRPF39 homodimer typically have shorter U1 snRNA compared to organisms with the heterodimer

  • This evolutionary shift correlates with increased splicing complexity in higher eukaryotes

What are the most reliable approaches for detecting endogenous PRPF39 expression across different tissues and cell types?

For reliable detection of endogenous PRPF39 expression:

• Tissue expression profiling:

  • PRPF39 mRNA is ubiquitously expressed in various tissues and cell lines according to the Human Protein Atlas

  • Expression levels fluctuate among tissues, potentially contributing to tissue-specific regulation of alternative splicing

  • Poison exon inclusion varies in different tissues (high in testis, low in lymph nodes)

• Multi-technique validation approach:

  • Combine RNA-seq data for transcript-level analysis

  • Validate protein expression with Western blot in subcellular fractions

  • Use immunohistochemistry to confirm tissue localization patterns

  • Consider qRT-PCR to quantify alternatively spliced PRPF39 isoforms

• Accounting for alternative splicing:

  • PRPF39 expression is controlled by NMD-inducing alternative splicing in mice and humans

  • A conserved "poison" exon leads to nonsense-mediated decay (NMD) when included

  • The inclusion of this exon varies in different tissues and cell states

  • In T cells, the poison exon is preferentially included in memory T cells compared to naïve T cells, potentially regulating differentiation

Why might I observe multiple bands when using PRPF39 antibodies in Western blots?

Multiple bands in Western blots using PRPF39 antibodies may result from:

• Alternative splicing:

  • PRPF39 undergoes alternative splicing, including a conserved "poison" exon

  • Different splice variants will produce proteins of varying lengths

  • Some variants may escape NMD and produce truncated proteins

• Post-translational modifications:

  • Phosphorylation or other modifications can alter protein migration

  • These modifications may be cell type or condition-specific

• Cross-reactivity or degradation:

  • Some antibodies may partially cross-react with related proteins

  • Proteolytic degradation during sample preparation can generate fragments

  • Test freshly prepared samples with protease inhibitors

• Validation approach:

  • Compare results with multiple PRPF39 antibodies targeting different epitopes

  • Include PRPF39 knockdown samples to identify specific bands

  • Use subcellular fractionation to check if bands correspond to different cellular compartments

What are the critical experimental controls when studying PRPF39's role in splicing?

To establish rigor in PRPF39 splicing studies:

• Knockdown validation controls:

  • Verify PRPF39 knockdown at both protein level (Western blot) and mRNA level (qRT-PCR)

  • Use multiple independent shRNAs or siRNAs with different knockdown efficiencies to establish dose-dependence

  • Include scrambled sequence controls

• Splicing event validation:

  • Confirm RNA-seq findings with RT-PCR for selected alternative splicing events

  • Include events from different categories (cassette exons, alternative 5' splice sites)

  • Calculate PSI values to quantify the extent of splicing changes

• Rescue experiments:

  • Reintroduce wild-type PRPF39 to rescue knockdown phenotypes

  • Test structure-guided mutants (e.g., dimerization-deficient) for rescue capability

  • Use silent mutations in the rescue construct to avoid targeting by the knockdown agent

• 5' splice site strength analysis:

  • Calculate 5' splice site strength scores for affected events

  • Compare the relative strength of competing splice sites

  • Correlate PRPF39 sensitivity with splice site strength and sequence composition

How can apparent discrepancies in PRPF39 function across different studies be reconciled?

To reconcile different findings regarding PRPF39 function:

• Cell type-specific effects:

  • PRPF39 expression and splicing activity may vary across cell types

  • The inclusion of the "poison" exon varies in different tissues, affecting PRPF39 levels

  • Expression levels of other splicing factors may influence PRPF39's relative contribution

• Experimental approach differences:

  • Complete knockout vs. partial knockdown may reveal different aspects of function

  • Acute vs. chronic depletion may allow for compensatory mechanisms

  • In vitro vs. in vivo studies may not fully recapitulate the native splicing environment

• Evolutionary considerations:

  • The function of PRPF39 has evolved from yeast to mammals

  • The metazoan PRPF39 homodimer functionally replaces the yeast Prp39/Prp42 heterodimer

  • Evolutionary adaptations correlate with changes in U1 snRNA length and splicing complexity

• Integration framework:

  • Consider PRPF39 as part of a larger splicing regulatory network

  • Multiple factors (TIA1, LUC7L) interact with both PRPF39 and U1 snRNP components

  • PRPF39 may have context-dependent roles based on available interacting partners

How is PRPF39 being investigated in disease contexts?

PRPF39 has emerging connections to disease processes:

• Cancer research:

  • PRPF39 has been identified as a key splicing factor in the correlation network of head and neck squamous cell carcinoma (HNSC)

  • Along with DDX39B and ARGLU1, PRPF39 regulates survival-associated alternative splicing events

  • A prognostic signature developed from survival-associated AS events could predict HNSC patient outcomes and clinical response to immunotherapy

• Immune system regulation:

  • The differential inclusion of PRPF39's "poison" exon in naïve vs. memory T cells suggests a role in immune cell differentiation

  • This regulatory mechanism potentially affects splicing efficiency in different immune cell states

• Research approaches:

  • Investigate PRPF39 expression and alternative splicing across tumor vs. normal tissues

  • Analyze correlation between PRPF39 levels and patient outcomes

  • Study PRPF39-dependent alternative splicing events in disease contexts

  • Explore PRPF39 as part of splicing factor networks in disease progression

What are the latest methodological advances for studying PRPF39 protein-protein and protein-RNA interactions?

Advanced approaches for studying PRPF39 interactions:

• Structural biology methods:

  • X-ray crystallography has resolved murine PRPF39 structure at 3.3 Å resolution

  • Cryo-EM approaches can investigate PRPF39 in the context of larger spliceosomal complexes

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) can map interaction interfaces

• Protein-RNA interaction methods:

  • CLIP-seq (Cross-linking immunoprecipitation followed by sequencing) can map PRPF39 binding sites transcriptome-wide

  • RNA Bind-n-Seq can determine PRPF39 binding motifs and preferences

  • Structure-guided mutagenesis of RNA-binding regions can dissect sequence specificity

• Protein-protein interaction approaches:

  • Proximity labeling methods (BioID, APEX) can identify the PRPF39 interactome in living cells

  • Co-immunoprecipitation followed by mass spectrometry can identify stable binding partners

  • Yeast two-hybrid or mammalian two-hybrid screens can find novel interactors

• Functional genomics integration:

  • Combine PRPF39 binding data with transcriptome-wide splicing changes

  • Correlate binding sites with splice site strength and sequence composition

  • Develop predictive models for PRPF39-dependent splicing regulation